$AVDL Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AVADEL PHARMACEUTICALS PLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in AVADEL PHARMACEUTICALS PLC. Get notifications about new insider transactions in AVADEL PHARMACEUTICALS PLC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 17 2021 | AVDL | AVADEL PHARMACEUTI ... | Kim Richard J | Chief Commercial Of ... | Option Exercise | A | 8.99 | 350,000 | 3,146,500 | 350,000 | |
Dec 23 2020 | AVDL | AVADEL PHARMACEUTI ... | Glass Geoffrey Michael | Director | Option Exercise | G | 8.48 | 42,000 | 356,160 | 0 | |
Dec 23 2020 | AVDL | AVADEL PHARMACEUTI ... | Glass Geoffrey Michael | Director | Option Exercise | G | 2.03 | 60,000 | 121,800 | 0 | |
Dec 23 2020 | AVDL | AVADEL PHARMACEUTI ... | Glass Geoffrey Michael | Director | Gift | G | 0.00 | 18,600 | 0 | 47,100 | 65.7 K to 47.1 K (-28.31 %) |
Dec 09 2020 | AVDL | AVADEL PHARMACEUTI ... | MCHUGH THOMAS S | Chief Financial Off ... | Option Exercise | A | 6.79 | 200,000 | 1,358,000 | 200,000 | |
Dec 09 2020 | AVDL | AVADEL PHARMACEUTI ... | Divis Gregory J | Chief Executive Off ... | Option Exercise | A | 6.79 | 500,000 | 3,395,000 | 500,000 | |
Sep 21 2020 | AVDL | AVADEL PHARMACEUTI ... | MCHUGH THOMAS S | Chief Financial Off ... | Buy | P | 6.00 | 4,000 | 24,000 | 21,500 | 17.5 K to 21.5 K (+22.86 %) |
Sep 18 2020 | AVDL | AVADEL PHARMACEUTI ... | McCamish Mark Anthony | Director | Buy | P | 5.83 | 52,398 | 305,250 | 171,000 | 118.6 K to 171 K (+44.18 %) |
Sep 18 2020 | AVDL | AVADEL PHARMACEUTI ... | McCamish Mark Anthony | Director | Buy | P | 5.73 | 118,602 | 679,969 | 118,602 | 0 to 118.6 K |
Sep 18 2020 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Buy | P | 5.79 | 17,000 | 98,376 | 84,900 | 67.9 K to 84.9 K (+25.04 %) |
Sep 14 2020 | AVDL | AVADEL PHARMACEUTI ... | McCamish Mark Anthony | Director | Option Exercise | A | 5.30 | 50,000 | 265,000 | 50,000 | |
Sep 01 2020 | AVDL | AVADEL PHARMACEUTI ... | MCHUGH THOMAS S | Chief Financial Off ... | Buy | P | 6.77 | 7,500 | 50,777 | 17,500 | 10 K to 17.5 K (+75.00 %) |
Sep 01 2020 | AVDL | AVADEL PHARMACEUTI ... | Glass Geoffrey Michael | Director | Buy | P | 6.78 | 4,800 | 32,560 | 65,700 | 60.9 K to 65.7 K (+7.88 %) |
Aug 17 2020 | AVDL | AVADEL PHARMACEUTI ... | MCHUGH THOMAS S | Chief Financial Off ... | Buy | P | 7.78 | 10,000 | 77,814 | 10,000 | 0 to 10 K |
Aug 17 2020 | AVDL | AVADEL PHARMACEUTI ... | Palczuk Linda | Director | Buy | P | 7.94 | 2,500 | 19,850 | 37,900 | 35.4 K to 37.9 K (+7.06 %) |
Aug 17 2020 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Buy | P | 7.80 | 3,800 | 29,640 | 67,900 | 64.1 K to 67.9 K (+5.93 %) |
Aug 17 2020 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Buy | P | 7.74 | 1,200 | 9,288 | 64,100 | 62.9 K to 64.1 K (+1.91 %) |
Aug 14 2020 | AVDL | AVADEL PHARMACEUTI ... | Glass Geoffrey Michael | Director | Buy | P | 7.76 | 6,500 | 50,440 | 60,900 | 54.4 K to 60.9 K (+11.95 %) |
Aug 14 2020 | AVDL | AVADEL PHARMACEUTI ... | Glass Geoffrey Michael | Director | Buy | P | 7.70 | 6,500 | 50,050 | 54,400 | 47.9 K to 54.4 K (+13.57 %) |
Aug 13 2020 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Buy | P | 7.76 | 15,000 | 116,355 | 62,900 | 47.9 K to 62.9 K (+31.32 %) |
Aug 13 2020 | AVDL | AVADEL PHARMACEUTI ... | Divis Gregory J | Chief Executive Off ... | Buy | P | 7.78 | 13,000 | 101,156 | 99,100 | 86.1 K to 99.1 K (+15.10 %) |
Aug 11 2020 | AVDL | AVADEL PHARMACEUTI ... | McCamish Mark Anthony | Director | Option Exercise | A | 8.48 | 42,000 | 356,160 | 42,000 | |
Aug 11 2020 | AVDL | AVADEL PHARMACEUTI ... | Thornton Peter J. | Director | Option Exercise | A | 8.48 | 42,000 | 356,160 | 42,000 | |
Aug 11 2020 | AVDL | AVADEL PHARMACEUTI ... | Glass Geoffrey Michael | Director | Option Exercise | A | 8.48 | 42,000 | 356,160 | 42,000 | |
Aug 11 2020 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Option Exercise | A | 8.48 | 42,000 | 356,160 | 42,000 | |
Aug 11 2020 | AVDL | AVADEL PHARMACEUTI ... | Palczuk Linda | Director | Option Exercise | A | 8.48 | 42,000 | 356,160 | 42,000 | |
Dec 16 2019 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Sell | S | 7.23 | 3,072 | 22,211 | 55,765 | 58.8 K to 55.8 K (-5.22 %) |
Dec 09 2019 | AVDL | AVADEL PHARMACEUTI ... | McCamish Mark Anthony | Director | Option Exercise | A | 5.92 | 60,000 | 355,200 | 60,000 | |
Dec 09 2019 | AVDL | AVADEL PHARMACEUTI ... | McCamish Mark Anthony | Director | Option Exercise | A | 5.92 | 60,000 | 355,200 | 60,000 | |
Dec 05 2019 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Buy | P | 5.97 | 10,000 | 59,700 | 47,900 | 37.9 K to 47.9 K (+26.39 %) |
Dec 05 2019 | AVDL | AVADEL PHARMACEUTI ... | Palczuk Linda | Director | Buy | P | 5.91 | 7,500 | 44,325 | 35,400 | 27.9 K to 35.4 K (+26.88 %) |
Dec 03 2019 | AVDL | AVADEL PHARMACEUTI ... | MCHUGH THOMAS S | Chief Financial Off ... | Option Exercise | A | 3.45 | 250,000 | 862,500 | 250,000 | |
Nov 19 2019 | AVDL | AVADEL PHARMACEUTI ... | Glass Geoffrey Michael | Director | Buy | P | 4.99 | 15,000 | 74,850 | 47,900 | 32.9 K to 47.9 K (+45.59 %) |
Nov 19 2019 | AVDL | AVADEL PHARMACEUTI ... | Glass Geoffrey Michael | Director | Buy | P | 4.99 | 5,000 | 24,950 | 32,900 | 27.9 K to 32.9 K (+17.92 %) |
Nov 19 2019 | AVDL | AVADEL PHARMACEUTI ... | DIVIS GREG J | Chief Executive Off ... | Buy | P | 5.13 | 19,000 | 97,470 | 86,100 | 67.1 K to 86.1 K (+28.32 %) |
Nov 19 2019 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Buy | P | 4.98 | 10,000 | 49,762 | 37,900 | 27.9 K to 37.9 K (+35.84 %) |
Nov 19 2019 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Buy | P | 4.98 | 10,000 | 49,762 | 37,900 | 27.9 K to 37.9 K (+35.84 %) |
Nov 14 2019 | AVDL | AVADEL PHARMACEUTI ... | Vaughn Jason | Sr. VP, Technical O ... | Option Exercise | A | 3.45 | 150,000 | 517,500 | 150,000 | |
Aug 09 2019 | AVDL | AVADEL PHARMACEUTI ... | Thornton Peter J. | Director | Option Exercise | A | 2.03 | 60,000 | 121,800 | 60,000 | |
Aug 09 2019 | AVDL | AVADEL PHARMACEUTI ... | Glass Geoffrey Michael | Director | Option Exercise | A | 2.03 | 60,000 | 121,800 | 60,000 | |
Aug 09 2019 | AVDL | AVADEL PHARMACEUTI ... | Palczuk Linda | Director | Option Exercise | A | 2.03 | 60,000 | 121,800 | 60,000 | |
Aug 09 2019 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Option Exercise | A | 2.03 | 60,000 | 121,800 | 60,000 | |
Aug 09 2019 | AVDL | AVADEL PHARMACEUTI ... | KOTLER KEVIN | Director | Option Exercise | A | 2.03 | 60,000 | 121,800 | 60,000 | |
Jun 03 2019 | AVDL | AVADEL PHARMACEUTI ... | DIVIS GREG J | Chief Executive Off ... | Option Exercise | A | 1.71 | 400,000 | 684,000 | 400,000 | |
May 24 2019 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Option Exercise | A | 1.49 | 8,057 | 12,005 | 8,057 | |
May 24 2019 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Grant | A | 0.00 | 27,900 | 0 | 27,900 | 0 to 27.9 K |
Apr 30 2019 | AVDL | AVADEL PHARMACEUTI ... | DUBOW JORDAN | Chief Medical Offic ... | Option Exercise | A | 1.44 | 340,000 | 489,600 | 340,000 | |
Apr 30 2019 | AVDL | AVADEL PHARMACEUTI ... | DUBOW JORDAN | Chief Medical Offic ... | Option Exercise | A | 1.44 | 340,000 | 489,600 | 340,000 | |
Mar 11 2019 | AVDL | AVADEL PHARMACEUTI ... | THOMPSON PHILLANDAS T. | See Remarks | Option Exercise | A | 1.85 | 100,000 | 185,000 | 100,000 | |
Mar 11 2019 | AVDL | AVADEL PHARMACEUTI ... | THOMPSON PHILLANDAS T. | See Remarks | Grant | A | 0.00 | 18,000 | 0 | 113,671 | 95.7 K to 113.7 K (+18.81 %) |
Mar 11 2019 | AVDL | AVADEL PHARMACEUTI ... | KANAN MICHAEL F | See Remarks | Option Exercise | A | 1.85 | 80,000 | 148,000 | 80,000 | |
Mar 11 2019 | AVDL | AVADEL PHARMACEUTI ... | KANAN MICHAEL F | See Remarks | Grant | A | 0.00 | 18,000 | 0 | 50,538 | 32.5 K to 50.5 K (+55.32 %) |
Mar 11 2019 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Option Exercise | A | 1.85 | 80,000 | 148,000 | 80,000 | |
Mar 11 2019 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Grant | A | 0.00 | 18,000 | 0 | 58,837 | 40.8 K to 58.8 K (+44.08 %) |
Mar 11 2019 | AVDL | AVADEL PHARMACEUTI ... | DIVIS GREG J | See Remarks | Option Exercise | A | 1.85 | 100,000 | 185,000 | 100,000 | |
Mar 11 2019 | AVDL | AVADEL PHARMACEUTI ... | DIVIS GREG J | See Remarks | Grant | A | 0.00 | 18,000 | 0 | 67,100 | 49.1 K to 67.1 K (+36.66 %) |
Feb 04 2019 | AVDL | AVADEL PHARMACEUTI ... | KOTLER KEVIN | Director | Grant | A | 0.00 | 27,900 | 0 | 3,130,573 | 3.1 M to 3.1 M (+0.90 %) |
Feb 04 2019 | AVDL | AVADEL PHARMACEUTI ... | Ende Eric J | Director | Grant | A | 0.00 | 27,900 | 0 | 27,900 | 0 to 27.9 K |
Dec 18 2018 | AVDL | AVADEL PHARMACEUTI ... | KANAN MICHAEL F | See Remarks | Sell | S | 2.49 | 8,429 | 21,022 | 29,538 | 38 K to 29.5 K (-22.20 %) |
Dec 18 2018 | AVDL | AVADEL PHARMACEUTI ... | GUSKY DAVID P | Controller & CAO | Sell | S | 2.68 | 617 | 1,656 | 4,083 | 4.7 K to 4.1 K (-13.13 %) |
Dec 18 2018 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Sell | S | 2.58 | 3,173 | 8,183 | 40,837 | 44 K to 40.8 K (-7.21 %) |
Aug 14 2018 | AVDL | AVADEL PHARMACEUTI ... | ANDERSON MICHAEL S | Chief Executive Off ... | Sell | S | 4.91 | 16,297 | 79,953 | 248,953 | 265.3 K to 249 K (-6.14 %) |
Aug 14 2018 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Sell | S | 4.91 | 6,290 | 30,859 | 44,010 | 50.3 K to 44 K (-12.50 %) |
Aug 14 2018 | AVDL | AVADEL PHARMACEUTI ... | ANDERSON MICHAEL S | Chief Executive Off ... | Sell | S | 4.91 | 16,297 | 79,953 | 248,953 | 265.3 K to 249 K (-6.14 %) |
Aug 14 2018 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Sell | S | 4.91 | 6,290 | 30,859 | 44,010 | 50.3 K to 44 K (-12.50 %) |
Aug 02 2018 | AVDL | AVADEL PHARMACEUTI ... | Thornton Peter J. | Director | Grant | A | 0.00 | 27,900 | 0 | 33,055 | 5.2 K to 33.1 K (+541.22 %) |
Aug 02 2018 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Grant | A | 0.00 | 27,900 | 0 | 378,228 | 350.3 K to 378.2 K (+7.96 %) |
Aug 02 2018 | AVDL | AVADEL PHARMACEUTI ... | Palczuk Linda | Director | Grant | A | 0.00 | 27,900 | 0 | 27,900 | 0 to 27.9 K |
Aug 02 2018 | AVDL | AVADEL PHARMACEUTI ... | Glass Geoffrey Michael | Director | Grant | A | 0.00 | 27,900 | 0 | 27,900 | 0 to 27.9 K |
Jul 11 2018 | AVDL | AVADEL PHARMACEUTI ... | VAN ASSCHE BENOIT | Director | Grant | A | 0.00 | 26,365 | 0 | 26,365 | 0 to 26.4 K |
Jul 11 2018 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Grant | A | 0.00 | 57,315 | 0 | 350,328 | 293 K to 350.3 K (+19.56 %) |
Jul 11 2018 | AVDL | AVADEL PHARMACEUTI ... | NAVARRE CHRISTOPHE | Director | Grant | A | 0.00 | 26,365 | 0 | 26,365 | 0 to 26.4 K |
Jul 11 2018 | AVDL | AVADEL PHARMACEUTI ... | FILDES FRANCIS | Director | Grant | A | 0.00 | 26,365 | 0 | 26,365 | 0 to 26.4 K |
Jun 29 2018 | AVDL | AVADEL PHARMACEUTI ... | KANAN MICHAEL F | See Remarks | Buy | P | 5.70 | 1,967 | 11,212 | 37,967 | 36 K to 38 K (+5.46 %) |
Jun 27 2018 | AVDL | AVADEL PHARMACEUTI ... | ANDERSON MICHAEL S | Chief Executive Off ... | Buy | P | 6.04 | 2,500 | 15,100 | 265,250 | 262.8 K to 265.3 K (+0.95 %) |
Jun 27 2018 | AVDL | AVADEL PHARMACEUTI ... | DIVIS GREG J | See Remarks | Buy | P | 6.00 | 16,000 | 96,000 | 49,100 | 33.1 K to 49.1 K (+48.34 %) |
Jun 27 2018 | AVDL | AVADEL PHARMACEUTI ... | THOMPSON PHILLANDAS T. | See Remarks | Buy | P | 5.77 | 10,000 | 57,700 | 91,000 | 81 K to 91 K (+12.35 %) |
Jun 25 2018 | AVDL | AVADEL PHARMACEUTI ... | Flynn James E | 10% Owner | Sell | S | 5.99 | 114,034 | 683,315 | 952,265 | 1.1 M to 952.3 K (-10.69 %) |
May 29 2018 | AVDL | AVADEL PHARMACEUTI ... | ANDERSON MICHAEL S | Chief Executive Off ... | Buy | P | 6.44 | 3,000 | 19,320 | 262,750 | 259.8 K to 262.8 K (+1.15 %) |
Mar 23 2018 | AVDL | AVADEL PHARMACEUTI ... | DIVIS GREG J | See Remarks | Option Exercise | A | 7.06 | 50,000 | 353,000 | 50,000 | |
Mar 05 2018 | AVDL | AVADEL PHARMACEUTI ... | GUSKY DAVID P | Controller & CAO | Option Exercise | A | 8.95 | 12,600 | 112,770 | 12,600 | |
Mar 05 2018 | AVDL | AVADEL PHARMACEUTI ... | GUSKY DAVID P | Controller & CAO | Grant | A | 0.00 | 2,700 | 0 | 4,700 | 2 K to 4.7 K (+135.00 %) |
Dec 19 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Grant | A | 8.67 | 70,000 | 606,970 | 180,000 | 110 K to 180 K (+63.64 %) |
Dec 19 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Grant | A | 8.67 | 70,000 | 606,970 | 323,413 | 253.4 K to 323.4 K (+27.62 %) |
Dec 14 2017 | AVDL | AVADEL PHARMACEUTI ... | KANAN MICHAEL F | See Remarks | Option Exercise | A | 8.95 | 80,000 | 716,000 | 80,000 | |
Dec 14 2017 | AVDL | AVADEL PHARMACEUTI ... | KANAN MICHAEL F | See Remarks | Grant | A | 0.00 | 18,000 | 0 | 36,000 | 18 K to 36 K (+100.00 %) |
Dec 14 2017 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Option Exercise | A | 8.95 | 60,000 | 537,000 | 60,000 | |
Dec 14 2017 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Grant | A | 0.00 | 12,500 | 0 | 50,300 | 37.8 K to 50.3 K (+33.07 %) |
Dec 14 2017 | AVDL | AVADEL PHARMACEUTI ... | DIVIS GREG J | See Remarks | Option Exercise | A | 8.95 | 100,000 | 895,000 | 100,000 | |
Dec 14 2017 | AVDL | AVADEL PHARMACEUTI ... | DIVIS GREG J | See Remarks | Grant | A | 0.00 | 22,500 | 0 | 33,100 | 10.6 K to 33.1 K (+212.26 %) |
Dec 14 2017 | AVDL | AVADEL PHARMACEUTI ... | THOMPSON PHILLANDAS T. | See Remarks | Option Exercise | A | 8.95 | 80,000 | 716,000 | 80,000 | |
Dec 14 2017 | AVDL | AVADEL PHARMACEUTI ... | THOMPSON PHILLANDAS T. | See Remarks | Grant | A | 0.00 | 18,000 | 0 | 81,000 | 63 K to 81 K (+28.57 %) |
Dec 14 2017 | AVDL | AVADEL PHARMACEUTI ... | ANDERSON MICHAEL S | Chief Executive Off ... | Option Exercise | A | 8.95 | 150,000 | 1,342,500 | 150,000 | |
Dec 14 2017 | AVDL | AVADEL PHARMACEUTI ... | ANDERSON MICHAEL S | Chief Executive Off ... | Grant | A | 0.00 | 25,000 | 0 | 259,750 | 234.8 K to 259.8 K (+10.65 %) |
Dec 11 2017 | AVDL | AVADEL PHARMACEUTI ... | ANDERSON MICHAEL S | Chief Executive Off ... | Buy | P | 8.86 | 5,000 | 44,295 | 234,750 | 229.8 K to 234.8 K (+2.18 %) |
Nov 29 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Sell | S | 9.35 | 254,265 | 2,377,632 | 253,413 | 507.7 K to 253.4 K (-50.08 %) |
Sep 25 2017 | AVDL | AVADEL PHARMACEUTI ... | Thornton Peter J. | Director | Buy | P | 9.74 | 5,155 | 50,215 | 5,155 | 0 to 5.2 K |
Sep 15 2017 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Buy | P | 9.15 | 1,200 | 10,980 | 3,400 | 2.2 K to 3.4 K (+54.55 %) |
Sep 15 2017 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Buy | P | 9.36 | 2,100 | 19,654 | 37,800 | 35.7 K to 37.8 K (+5.88 %) |
Sep 15 2017 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Buy | P | 9.35 | 500 | 4,673 | 35,700 | 35.2 K to 35.7 K (+1.42 %) |
Sep 15 2017 | AVDL | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Buy | P | 9.19 | 2,200 | 20,218 | 35,200 | 33 K to 35.2 K (+6.67 %) |
Sep 14 2017 | AVDL | AVADEL PHARMACEUTI ... | THOMPSON PHILLANDAS T. | See Remarks | Buy | P | 9.36 | 5,000 | 46,800 | 63,000 | 58 K to 63 K (+8.62 %) |
Sep 14 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Buy | P | 9.52 | 20,000 | 190,360 | 110,000 | 90 K to 110 K (+22.22 %) |
Sep 14 2017 | AVDL | AVADEL PHARMACEUTI ... | DIVIS GREG J | See Remarks | Buy | P | 9.32 | 10,600 | 98,760 | 10,600 | 0 to 10.6 K |
Sep 14 2017 | AVDL | AVADEL PHARMACEUTI ... | ANDERSON MICHAEL S | Chief Executive Off ... | Buy | P | 9.80 | 4,000 | 39,180 | 229,750 | 225.8 K to 229.8 K (+1.77 %) |
Jun 30 2017 | AVDL | AVADEL PHARMACEUTI ... | FILDES FRANCIS | Director | Option Exercise | A | 10.51 | 30,000 | 315,300 | 30,000 | |
Jun 30 2017 | AVDL | AVADEL PHARMACEUTI ... | VAN ASSCHE BENOIT | Director | Option Exercise | A | 10.51 | 30,000 | 315,300 | 30,000 | |
Jun 30 2017 | AVDL | AVADEL PHARMACEUTI ... | NAVARRE CHRISTOPHE | Director | Option Exercise | A | 10.51 | 30,000 | 315,300 | 30,000 | |
Jun 30 2017 | AVDL | AVADEL PHARMACEUTI ... | Thornton Peter J. | Director | Option Exercise | A | 10.51 | 30,000 | 315,300 | 30,000 | |
Jun 30 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Option Exercise | A | 10.51 | 30,000 | 315,300 | 30,000 | |
Jun 26 2017 | AVDL | AVADEL PHARMACEUTI ... | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 10.60 | 161,000 | 1,706,600 | 4,133,464 | 4.3 M to 4.1 M (-3.75 %) |
Jun 26 2017 | AVDL | AVADEL PHARMACEUTI ... | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | S | 10.80 | 100,000 | 1,080,000 | 4,294,464 | 4.4 M to 4.3 M (-2.28 %) |
Jun 19 2017 | AVDL | AVADEL PHARMACEUTI ... | CERUTTI GUILLAUME | Director | Sell | S | 10.46 | 26,560 | 277,818 | 23,440 | 50 K to 23.4 K (-53.12 %) |
May 22 2017 | AVDL | AVADEL PHARMACEUTI ... | ANDERSON MICHAEL S | Chief Executive Off ... | Buy | P | 10.00 | 2,500 | 25,000 | 225,750 | 223.3 K to 225.8 K (+1.12 %) |
May 22 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Buy | P | 9.76 | 16,900 | 164,944 | 90,000 | 73.1 K to 90 K (+23.12 %) |
May 22 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Buy | P | 9.83 | 3,100 | 30,473 | 73,100 | 70 K to 73.1 K (+4.43 %) |
May 22 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Buy | P | 9.98 | 11,013 | 109,910 | 70,000 | 59 K to 70 K (+18.67 %) |
May 18 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Grant | A | 9.95 | 12,100 | 120,393 | 58,987 | 46.9 K to 59 K (+25.81 %) |
May 18 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Grant | A | 10.00 | 3,470 | 34,700 | 46,887 | 43.4 K to 46.9 K (+7.99 %) |
May 16 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Grant | A | 10.00 | 311 | 3,110 | 43,417 | 43.1 K to 43.4 K (+0.72 %) |
May 16 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Grant | A | 10.00 | 3,106 | 31,060 | 43,106 | 40 K to 43.1 K (+7.77 %) |
Apr 05 2017 | AVDL | AVADEL PHARMACEUTI ... | STAPLETON CRAIG R | Director | Grant | A | 9.58 | 15,000 | 143,643 | 507,678 | 492.7 K to 507.7 K (+3.04 %) |
Jan 06 2017 | FLML | AVADEL PHARMACEUTI ... | Broadfin Healthcare Master Fun ... | 10% Owner | Sell | D | 0.00 | 4,394,464 | 0 | 0 | 4.4 M to 0 (-100.00 %) |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | GUSKY DAVID P | See Remarks | Option Exercise | A | 10.40 | 14,000 | 145,600 | 14,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | GUSKY DAVID P | See Remarks | Option Exercise | A | 7.85 | 50,000 | 392,500 | 50,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | GUSKY DAVID P | See Remarks | Grant | A | 0.00 | 2,000 | 0 | 2,000 | 0 to 2 K |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Option Exercise | A | 10.40 | 80,000 | 832,000 | 80,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Option Exercise | A | 14.35 | 50,000 | 717,500 | 50,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Option Exercise | A | 21.67 | 100,000 | 2,167,000 | 100,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | Hatten Sandra L | See Remarks | Grant | A | 0.00 | 33,000 | 0 | 33,000 | 0 to 33 K |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | THOMPSON PHILLANDAS T. | See Remarks | Option Exercise | A | 10.40 | 100,000 | 1,040,000 | 100,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | THOMPSON PHILLANDAS T. | See Remarks | Option Exercise | A | 14.35 | 100,000 | 1,435,000 | 100,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | THOMPSON PHILLANDAS T. | See Remarks | Option Exercise | A | 16.30 | 95,000 | 1,548,500 | 95,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | THOMPSON PHILLANDAS T. | See Remarks | Option Exercise | A | 7.36 | 100,000 | 736,000 | 100,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | THOMPSON PHILLANDAS T. | See Remarks | Grant | A | 0.00 | 58,000 | 0 | 58,000 | 0 to 58 K |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | SULLIVAN STEPHEN G. | See Remarks | Option Exercise | A | 10.40 | 65,000 | 676,000 | 65,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | SULLIVAN STEPHEN G. | See Remarks | Option Exercise | A | 23.53 | 50,000 | 1,176,500 | 50,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | SULLIVAN STEPHEN G. | See Remarks | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | FILDES FRANCIS | Director | Option Exercise | A | 21.67 | 54,026 | 1,170,743 | 54,026 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | FILDES FRANCIS | Director | Option Exercise | A | 14.54 | 46,000 | 668,840 | 46,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | FILDES FRANCIS | Director | Grant | A | 0.00 | 15,000 | 0 | 15,000 | 30 K to 15 K (-50.00 %) |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | DAVIS GREGORY J. | See Remarks | Option Exercise | A | 10.40 | 65,000 | 676,000 | 65,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | DAVIS GREGORY J. | See Remarks | Option Exercise | A | 14.35 | 50,000 | 717,500 | 50,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | DAVIS GREGORY J. | See Remarks | Option Exercise | A | 21.67 | 50,000 | 1,083,500 | 50,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | DAVIS GREGORY J. | See Remarks | Grant | A | 0.00 | 30,000 | 0 | 30,000 | 0 to 30 K |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | Elrod Marcus W | See Remarks | Option Exercise | A | 10.40 | 22,000 | 228,800 | 22,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | Elrod Marcus W | See Remarks | Option Exercise | A | 13.59 | 100,000 | 1,359,000 | 100,000 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | Elrod Marcus W | See Remarks | Grant | A | 0.00 | 3,400 | 0 | 3,400 | 0 to 3.4 K |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | VAN ASSCHE BENOIT | Director | Option Exercise | A | 21.67 | 54,026 | 1,170,743 | 54,026 | |
Jan 03 2017 | FLML | AVADEL PHARMACEUTI ... | VAN ASSCHE BENOIT | Director | Option Exercise | A | 14.54 | 46,000 | 668,840 | 46,000 |